25.5 bn
revenue in 2021    
revenue growth in 2021
Binnopharm Group’s shareholders are Sistema (75.3%), VTB Capital (11.2%), and the Russian Direct Investment Fund with co-investors (12.5%)

Financial results

Unaudited condensed interim consolidated financial statements for 6M ended 30 June 2021
Combined and consolidated financial statements for 2020 and an independent auditor's report


Binnopharm Group’s credit ratings are assigned by rating agencies based on the assessment of the Company's strategy, development plans, current leverage and financial stability

Expert RA
Outlook stable
In accordance with the Russian law, Binnopharm Group publishes information subject to disclosure by Issuers of Issue-Grade Securities on the website
https://www.e-disclosure.ru/portal/company.aspx?id=38507 of the security market information provider Interfax-CIDC certified by the Bank of Russia for disclosure purposes. Any information published on this website is for informational purposes only and may not be considered a public offer as defined in Clause 437 of the Russian Civil Code.